Lasa Supergenerics Limited has announced a key leadership appointment, naming Mrs. Mitti Jain as the company's new Company Secretary and Compliance Officer. The appointment takes effect from December 16, 2025, and was communicated to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Lasa Supergenerics has appointed Mrs. Jain pursuant to Section 203 of the Companies Act, 2013 and Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. She will also serve as Key Managerial Personnel of the company.

Professional Background

Mrs. Mitti Jain brings substantial expertise to her new role at Lasa Supergenerics, with 10 years of rich experience in corporate laws and allied matters. She is an Associate Member of the Institute of Company Secretaries of India (ICSI), demonstrating her professional qualifications in corporate governance and compliance matters.

Educational and Professional Credentials

• Professional Qualification: Associate Member of Institute of Company Secretaries of India
• Educational Background: B.Com and M.Com degrees from University of Gujarat
• Experience: 10 years of experience in corporate law

Regulatory Compliance

The appointment announcement was made in compliance with SEBI circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015. The company has fulfilled its disclosure obligations by informing both BSE Limited and National Stock Exchange of India Limited about this key managerial appointment.

The information regarding this appointment is also available on the company's website at www.lasalabs.com and on the stock exchange websites. This appointment strengthens Lasa Supergenerics' corporate governance framework with an experienced professional overseeing compliance and secretarial functions.

Lasa Supergenerics Limited has announced the resignation of its Whole-time Director Mr. Prathmesh Chalke, effective December 31, 2025. The pharmaceutical company informed both BSE and NSE about this key management change in compliance with regulatory requirements.

Director Resignation Details

The company filed the resignation intimation under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The resignation becomes effective from the closing hours of Wednesday, December 31, 2025.

Resignation Communication

In his resignation letter dated December 11, 2025, Mr. Chalke expressed his intention to step down from his directorial position. He confirmed that there are no material reasons for his resignation beyond those provided in his resignation communication to the company.

The departing director stated his gratitude for the opportunities, growth, and experience gained during his tenure with the company. He has committed to ensuring a smooth handover process and completing any pending tasks before his departure.

Regulatory Compliance

The company has fulfilled its disclosure obligations by informing both stock exchanges where its shares are listed:

• BSE Limited (Code: 540702)
• National Stock Exchange (Code: LASA)

The resignation details and supporting documentation have been made available on the company's website at www.lasalabs.com as part of transparency requirements.

Company Leadership

The resignation intimation was signed by Mr. Omkar Pravin Herlekar (DIN: 01587154), who serves as Chairman and Managing Director of Lasa Supergenerics Limited. The company is headquartered at C-4, C-4/1, M.I.D.C. Lote Parshuram Industrial Area, Tal-Khed, Dist-Ratnagiri 415722.